Loading ...
New Study RevealsHow ... LedAntibody Treatment
to block the spread of tangle formation through the brain(passive) is designedAbbVie 's antibody
actionultimately causingantibody release
from the mouse tissue(passive) is originatedPMP70 ) Polyclonal Antibody
The companydiscoversmonoconal antibody
utilizing a proprietary human memory B cell platformto discoverantibody therapeutics
which structural computational methodsto designantibody therapeutics
by the passive infusion of antibodies from the donor reacting with the cognate antigen of the recipient(passive) is caused byAntibody mediated
for indirect immunofluorescence analysis by Flow Cytometry(passive) is designedBiotinylated antibody
ScientistsDiscoverAntibody Infusion
y robertcontributeantibody - coated
the factorsinfluenceantibody titer
the factorsinfluencingantibody titer
Further analysis of the factorsinfluenceantibody titer
the composition of the culture media(passive) is significantly influenced byAntibody glycosylation
chemiluminscence ( 4(passive) was discovered byAntibody presenting
to block the functional activity of SEMA4D.(passive) is designedVX15 antibody
The targeting unit appearedto influenceantibody isotype
of two heavy ( H ) and two light ( L ) chains(passive) is composedantibody
by the formation of complexes of antigen with antibody or by transient suppression of antibody synthesis(passive) caused byantibody
by enzyme - linked immunosorbent assay ( ELISA(passive) discovered byantibody
by natural infection(passive) caused byantibody
natural infection(passive) caused byantibody
chemiluminscence using the Supersignal chemiluminscent substrate ( ThermoScientific , Rockford , IL ) as referred to ( 4(passive) was discovered byAntibody presenting
by the vaccine(passive) caused byantibody
Researchersdiscoverantibody
in a human(passive) was discoveredantibody
- Scientistsdiscoverantibody
Scientistsdiscoverantibody ...
Scientistsdiscoverantibody
Scientists Scientistsdiscoverantibody
MORE HERE Scientistsdiscoverantibody
the presence of AIDS ... and antigenscausingantibody
by vaccination(passive) caused byantibody
vaccination(passive) caused byantibody
of sugar chains and polypeptide chains(passive) is composedAntibody
the mechanism ... this rejection processwhereby ... causesantibody
Post Scientistsdiscoverantibody
to block the functional activity of SEMA4D. The SIGNAL clinical trial will build upon preclinical studies in an animal model of HD and safety data from a Phase 1 dose - escalation clinical trial of VX15 in MS patients that we completed in November 2014(passive) is designedVX15 antibody
to block the functional activity of SEMA4D. The SIGNAL clinical trial will build upon preclinical studies in an animal model of HD and safety data from a Phase 1 dose - escalation clinical trial of VX15 in MS patients that was completed in November 2014(passive) is designedVX15 antibody
in a reduction of myocardial infarct sizeresultedin a reduction of myocardial infarct size
to increased tau phosphorylation and neuronal lossledto increased tau phosphorylation and neuronal loss
increased permeabilitycausesincreased permeability
in an overall response rate of 60 percentresultedin an overall response rate of 60 percent
in rapid onset of severe arthritisresultedin rapid onset of severe arthritis
in depletion of B cellsresultsin depletion of B cells
to selectively target CD20-positive B cellsdesignedto selectively target CD20-positive B cells
to nonspecific cellular activationcan leadto nonspecific cellular activation
to selectively target CD20-positive B cells , a specific type of immune cell thought to be a key contributor to myelin and axonal ( nerve cell ) damage , which can lead to disability in people with MSdesignedto selectively target CD20-positive B cells , a specific type of immune cell thought to be a key contributor to myelin and axonal ( nerve cell ) damage , which can lead to disability in people with MS
to selectively target CD20-positive B cells , a specific type of immune cell thought to be a key contributor to myelin and nerve cell damage , which can lead to disability in people with MSdesignedto selectively target CD20-positive B cells , a specific type of immune cell thought to be a key contributor to myelin and nerve cell damage , which can lead to disability in people with MS
downregulation of pax[b ] transcriptscausesdownregulation of pax[b ] transcripts
the progressive fall of the dark current , together with the progressive slowing down of the flash response kineticscausedthe progressive fall of the dark current , together with the progressive slowing down of the flash response kinetics
to treat cancerdesignedto treat cancer
downregulation of pax[b ] transcripts in the posterior midbrain and alteration of wnt-1causesdownregulation of pax[b ] transcripts in the posterior midbrain and alteration of wnt-1
to assess protein profiling ( global regulation and post - translational modifications ) in cells , biopsies and biological fluidsdesignedto assess protein profiling ( global regulation and post - translational modifications ) in cells , biopsies and biological fluids
to a > 70 % lossledto a > 70 % loss
charge heterogeneitycould causecharge heterogeneity
the thyroglobulin level to be artificially suppressedwill causethe thyroglobulin level to be artificially suppressed
of PBS containing 5 % serum and 1 %composedof PBS containing 5 % serum and 1 %
stronglyinfluencestrongly
to the production of antigen - antibody complexesleadingto the production of antigen - antibody complexes
humoral pathways of inflammationmay influencehumoral pathways of inflammation
in specific staining of protein bandsresultedin specific staining of protein bands
to bind to PD - L1 and a non - disclosed second immunomodulatory targetdesignedto bind to PD - L1 and a non - disclosed second immunomodulatory target
destruction of the antigen 1 ) Neutralization a ) Bindcausesdestruction of the antigen 1 ) Neutralization a ) Bind
the ADC to bind to the target cancer cellscausesthe ADC to bind to the target cancer cells
to cellular destruction by binding complementcan also leadto cellular destruction by binding complement
to bind to a single targetdesignedto bind to a single target
to bind to a single target designedto bind to a single target
a visible reaction with a specific antigencausinga visible reaction with a specific antigen
significant cell killing in vitrocausessignificant cell killing in vitro
earlier or more extensive imaging in patients with increasing titersmay promptearlier or more extensive imaging in patients with increasing titers
to be a more specific treatmentdesignedto be a more specific treatment
destruction of the antigencausesdestruction of the antigen
clumping or agglutination of the bacteria or other cellscausesclumping or agglutination of the bacteria or other cells
in precipitation with no excess antibody or antigenresultsin precipitation with no excess antibody or antigen
to increased survivalledto increased survival
to HIV vaccinecould leadto HIV vaccine
false test positive reactioncausingfalse test positive reaction
to bind to a singledesignedto bind to a single